C4 Therapeutics (CCCC) Interest Expenses (2019 - 2026)

C4 Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 3.02% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $136000.0, a 101.79% increase from a year earlier, with the FY2025 full-year figure at $203.6 million, up 17.34% from the prior year.
• Interest Expenses advanced to $2.3 million in Q1 2026 per CCCC's latest filing, from $59000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $103.9 million in Q1 2022 and bottomed at -$6.6 million in Q4 2024.
• The 5-year median for Interest Expenses is $911000.0 (2023), against an average of $17.8 million.
• Biggest YoY gain for Interest Expenses was 2002.71% in 2022; the steepest drop was 1553.36% in 2022.
• Year by year, Interest Expenses stood at -$3.5 million in 2022, then slumped by 57.01% to -$5.4 million in 2023, then retreated by 21.78% to -$6.6 million in 2024, then soared by 100.89% to $59000.0 in 2025, then jumped by 3827.12% to $2.3 million in 2026.
• Per Business Quant, the three latest CCCC Interest Expenses figures stand at $2.3 million (Q1 2026), $59000.0 (Q4 2025), and $9000.0 (Q3 2025).